Skip to content

Study · Not a test of the peptide alone · 2019

3 results

Disrupted hippocampal growth hormone secretagogue receptor 1α interaction with dopamine receptor D1 plays a role in Alzheimer's disease.

Tian J, Guo L, Sui S, Driskill C, Phensy A, Wang Q, Gauba E, Zigman JM, Swerdlow RH, Kroener S, Du H

Science translational medicine1 Aug 2019Cited by 50 (Europe PMC)

PMID31413143 (opens in a new tab)PMCIDPMC6776822 (opens in a new tab)DOI10.1126/scitranslmed.aav6278 (opens in a new tab)PepBankPUB-31413143
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MK-677 (ibutamoren).

  1. 01AnimalNot a test of MK-677 (ibutamoren) aloneAnimal study (in vivo)Efficacy outcome

    In an AD mouse model, MK0677 with SKF81297 rescued Ghsr1α function from Aβ inhibition.

    In plain wordsIn mice with an Alzheimer's disease model, MK0677 with SKF81297 restored receptor function inhibited by amyloid.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseGhsr1α function
    Study

    mousen: not reported in source

    Alzheimer's disease mouse model
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    The simultaneous application of the selective GHSR1α agonist MK0677 with the selective DRD1 agonist SKF81297 rescued Ghsr1α function from Aβ inhibition, mitigating hippocampal synaptic injury and improving spatial memory in an AD mouse model.

    In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).

  2. 02AnimalNot a test of MK-677 (ibutamoren) aloneAnimal study (in vivo)Efficacy outcome

    In an AD mouse model, MK0677 with SKF81297 mitigated hippocampal synaptic injury.

    In plain wordsIn mice with an Alzheimer's disease model, MK0677 with SKF81297 reduced hippocampal synaptic injury.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    DecreaseHippocampal synaptic injury
    Study

    mousen: not reported in source

    Alzheimer's disease mouse model
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    The simultaneous application of the selective GHSR1α agonist MK0677 with the selective DRD1 agonist SKF81297 rescued Ghsr1α function from Aβ inhibition, mitigating hippocampal synaptic injury and improving spatial memory in an AD mouse model.

    In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).

  3. 03AnimalNot a test of MK-677 (ibutamoren) aloneAnimal study (in vivo)Efficacy outcome

    In an AD mouse model, MK0677 with SKF81297 improved spatial memory.

    In plain wordsIn mice with an Alzheimer's disease model, MK0677 with SKF81297 improved spatial memory.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseSpatial memory
    Study

    mousen: not reported in source

    Alzheimer's disease mouse model
    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    The simultaneous application of the selective GHSR1α agonist MK0677 with the selective DRD1 agonist SKF81297 rescued Ghsr1α function from Aβ inhibition, mitigating hippocampal synaptic injury and improving spatial memory in an AD mouse model.

    In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.